Form 4 for CADL Candel Therapeutics, Inc.

Accepted 2021-08-02 00:00:00 ET · period of report 2021-07-29 · accession 0000899243-21-031088 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-08-02	2021-07-29	CADL	Aguilar Laura K.	Chief Medical Off	C - Cnv Deriv	—	+56.1K	931.0K	+6%	—
D	2021-08-02	2021-07-29	CADL	Aguilar Laura K.	Chief Medical Off	C - Cnv Deriv	$0.00	-137.9K	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-29	C	A	56,096	—	931,039	D	—	—	(F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. (F2) Includes 32,399 shares of common stock held jointly with spouse.
2	Derivative	Series B Preferred Stock	2021-07-29	C	D	137,881	$0.00	0	D	— · — to —	56,096 Common Stock	(F2) Includes 32,399 shares of common stock held jointly with spouse. (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.